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INTRODUCTION
Intraocular neovascular diseases are the leading cause of blindness 
in the Western world in individuals over the age of 50. Exudative 
age-related macular degeneration (AMD) is one of these diseases 
and is characterized by aberrant neovessel development, sprout-
ing from the choroidal vessels into the subretinal space through a 
fragmented Bruch’s membrane. Without treatment such new ves-
sel formation, called choroidal neovascularization (CNV), can cause 
irreversible damage to the vulnerable photoreceptor cells essen-
tial for high-resolution, central vision. The advent of anti-vascular 
endothelial growth factor (VEGF) therapy has markedly changed 
the outcome of treatment, and the success has positioned VEGF at 
the epicenter of research for new treatment modalities for retinal 
vascular diseases.
Despite the high success rate, clinicians still examine eyes that are 
only partially responsive or even nonresponsive to antibody-based 
anti-VEGF therapy, underscoring the need for a new and refined 
treatment. Recently, several studies have been published, examin-
ing the outcome of combined or triple therapy for the treatment of 
exudative AMD.1–3 The rationale behind utilization of combination 
therapies relates to the different mechanism of action of the com-
bined therapies. The complexity of pathogenic neovascularization, 
including the numerous complex pathways mediating the effect of 
VEGF, indicates that simultaneous targeting of different pathways 
of this process may have synergistic effects and thus improve visual 
outcome and/or reduce treatment frequency.
The potential of RNA interference (RNAi) therapy for a broad range 
of diseases has led to clinical trials evaluating the safety and efficacy 
of three short interfering RNAs (siRNA) for treatment of exudative 
AMD.4–6 The safety data have been encouraging, but phase II and III 
clinical trials testing AGN211745 and bevasiranib, respectively, were 
terminated due insufficient efficacy of the siRNA monotherapy. 
However, combined therapy of ranibizumab and siRNA was found 
to be superior to ranibizumab monotherapy, which is currently the 
standard treatment.7,8 In these trials, naked siRNA was delivered 
by intravitreal injections with the drawback of multiple injections 
just as conventional treatments. Another concern regarding siRNA-
based therapy was raised when it was discovered that suppression 
of CNV does not occur through the specific action of the siRNA tar-
geting VEGF, but rather as a generic, sequence-independent prop-
erty of the noninternalized siRNAs.9
We and others have previously shown, that anti-VEGF short hair-
pin RNAs (shRNAs) encoded by viral vectors can reduce CNV in mice 
following a single injection.4,10,11 Additionally, we have shown that 
adenoassociated viral (AAV)-mediated delivery of an anti-VEGF 
microRNA (miRNA) cluster can knockdown endogenous VEGF 
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Lentivirus-based gene delivery vectors carrying multiple gene cassettes are powerful tools in gene transfer studies and gene 
therapy, allowing coexpression of multiple therapeutic factors and, if desired, fluorescent reporters. Current strategies to express 
transgenes and microRNA (miRNA) clusters from a single vector have certain limitations that affect transgene expression levels 
and/or vector titers. In this study, we describe a novel vector design that facilitates combined expression of therapeutic RNA- and 
protein-based antiangiogenic factors as well as a fluorescent reporter from back-to-back RNApolII-driven expression cassettes. This 
configuration allows effective production of intron-embedded miRNAs that are released upon transduction of target cells. Exploit-
ing such multigenic lentiviral vectors, we demonstrate robust miRNA-directed downregulation of vascular endothelial growth 
factor (VEGF) expression, leading to reduced angiogenesis, and parallel impairment of angiogenic pathways by codelivering the 
gene encoding pigment epithelium-derived factor (PEDF). Notably, subretinal injections of lentiviral vectors reveal efficient retinal 
pigment epithelium-specific gene expression driven by the VMD2 promoter, verifying that multigenic lentiviral vectors can be 
produced with high titers sufficient for in vivo applications. Altogether, our results suggest the potential applicability of combined 
miRNA- and protein-encoding lentiviral vectors in antiangiogenic gene therapy, including new combination therapies for ameliora-
tion of age-related macular degeneration.
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in a mouse model.12 To achieve synergy in a genetic intervention 
approach, we explore in this study means of combining RNAi-based 
silencing of VEGF, which is upregulated during pathological con-
ditions, with delivery of therapeutic proteins. Such proteins could 
be antiangiogenic, antiinflammatory, or for instance neurotrophic 
such as the protein pigment epithelium-derived factor. We engineer 
multigenic LV vectors and demonstrate the potential of combining 
multiple miRNAs with protein expression for combined antiangio-
genic activity. We show efficient knockdown of VEGF in vitro and 
provide in vivo evidence for localized transgene expression follow-
ing incorporation of the retinal pigment epithelium-specific vitel-
liform macular dystrophy 2 (VMD2) promoter into the vector. These 
results have potential implications for the future development of 
gene delivery vehicles for combination therapy of neovascular dis-
eases, including exudative AMD.
ReSUlTS
Multigenic LV vectors are functional and versatile gene delivery 
vehicles
We generated multigenic LV constructs by inserting an addi-
tional AsRed-encoding expression cassette in reverse orienta-
tion in a pCCL-based LV transfer plasmid, here designated pLV/
PE (Figure  1a). Between the promoter and the AsRed coding 
sequence, we inserted a modified β-globin intron containing a 
linker sequence for insertion of intronic miRNA clusters. Effective 
and precise splicing of the pre-mRNA was confirmed by PCR. 
Primers were designed to bind in the 5′ exon region of the β-globin 
exon-intron-exon sequence and in the region of a red fluorescent 
protein, AsRED (Figure 1a), amplifying a short fragment of 791 bp 
indicative of splicing, as opposed to a longer fragment of 1,270 bp 
in the absence of splicing (Figure 1b). Only the short PCR prod-
uct was observed when cDNA was used as a template, whereas a 
longer PCR product was generated in the control using plasmid 
DNA as template. This indicates correct splicing of the expressing 
cassette, allowing for processing of the miRNA cluster (see below).
Titer assessment of different LV preparations was performed by 
flow cytometry analysis of cells transduced with serially diluted 
viral preparations (Figure 1c) and p24 ELISA (see Materials and 
Methods). The amount of p24 determined by ELISA for each LV 
preparation was found to range from 1.6 × 105 to 1.1 × 106 pg p24/
ml, and the effective titer ranged from 6.2 × 105 to 1.6 × 107 TU/ml. 
The highest effective titers were obtained for LV/PE, but vectors 
carrying the CMV-intron cassette were effectively transferred with 
titers that were reduced up to 12-fold relative to LV/PE. Notably, 
neither insertion of the triple miRNA encoding sequences in 
the intron nor the actual sequence of the miRNA insert did not 
adversely affect the effective titer (Figure 1c).
For RPE-specific expression in vivo, the CMV promoter 
was replaced with the VMD2 promoter. AsRED was inserted 
to assess cell-specific expression from the VMD2 promoter. 
Immunofluorescence analysis of eGFP and AsRED expression in 
three different human cell lines, HEK-293, ARPE-19, and mela-
noma13 cells, was investigated 4 days after transduction with 
LV/VMD2-intron-AsRED-PE (Figure 1d). Robust eGFP expression 
indicated sufficient transduction of all cell lines, but high lev-
els of AsRED expression were found only in melanoma cells, and 
not in ARPE-19 cells, indicating profound cell-specific expression 
from the VMD2 promoter. This finding was not unexpected, since 
expression levels of transcription factors and the VMD2 gene itself 
differ significantly in the ARPE-19 cell line compared to primary 
RPE cells.14
These results demonstrated that after transcription the intron 
was spliced out and a functional protein, in this case AsRED, was 
produced. Hence, the vector system is highly versatile, and replace-
ment of either transgene or miRNA cluster does not profoundly 
affect the titer. This allows for easy manipulation of vector elements 
and tailoring of the vector for a broad range of specific applications.
Multigenic LV vectors efficiently transduce cells in the outer retina 
following subretinal delivery in mice
Based on the development of a highly versatile LV vector, we 
wanted to investigate whether the titer obtained for such complex 
LV vectors was sufficient for in vivo transgene expression. To assess 
transgene expression in the mouse retina, four eyes of mice were 
injected with 30 ng p24 LV/VMD2-miR(5,B,7)-AsRED-PE (Figure 2). 
To determine which cells of the retina the LV vectors transduced, 
frozen sagittal sections of injected retinas were analyzed 21 days 
after injection by fluorescence microscopy. Robust expression of 
eGFP and AsRED was evident in the retina but, as expected, limited 
to the area in vicinity of the injection site (Figure 2a–c). Additionally, 
a magnified image of the retina depicting eGFP and AsRED signals 
revealed eGFP expression in transduced cells in the inner and outer 
nuclear layers including the RPE cells, whereas the AsRED signal 
was found exclusively in RPE cells in the investigated eyes (compare 
Figure 2d and 2e). These results demonstrated that the achieved 
titers of multigenic LV vectors were sufficient for in vivo applications 
and that efficient transgene expression was limited to RPE cells 
when the expression was driven by the VMD2 promoter following 
subretinal vector delivery.
miRNAs from the anti-VEGF miR-(5,B,7) cluster are efficiently 
processed from the LV vectors and can knockdown VEGF
Coexpression of multiple miRNAs from an RNA polymerase II pro-
moter is possible when utilizing a polycistronic miRNA cluster. In 
a previous study, we have tested the efficacy of shRNA-mediated 
VEGF knockdown of ten different shRNAs using the dual-luciferase 
assay, and subsequently generated anti-VEGF miRNA clusters by 
combining the three most potent target sites in the human VEGF 
(hVEGF) in an optimized, tricistronic MCM7-based miRNA  cluster.12 
In this study, we modified this tricistronic miR-5,10,7 targeting 
hVEGF165 to generate the miR(5,B,7) expressing vector target-
ing murine VEGF164 (mVEGF) by replacing each of the anti-hVEGF 
miRNAs with murine targeting anti-mVEGF miRNAs. miR-10 was 
replaced by miR-B, a miR-93-mimic designed to release a miRNA 
targeting the same position in mVEGF as bevasiranib4 (formerly 
Cand5, OPKO Health), a novel siRNA used for treatment of wet AMD. 
The HIV-targeting MCM7-based miRNA cluster, miR(S1,S2,S3), was 
used as an irrelevant, nontargeting negative control (referred to as 
miR-Irr in this study).15
Functional expression of miRNAs from the cluster was tested by 
cotransfecting HEK-293 cells with pcDNA3.1-based plasmids express-
ing the different miRNA clusters and the dual luciferase psiCHECK 
reporter construct, psiCHECK-mVEGF (see Materials and Methods). As 
shown in Figure 3a, an improved gene silencing effect was observed 
by combining two or three miRNAs in the cluster. We achieved a sig-
nificant mVEGF knockdown by all seven miRNA clusters generated 
in this study compared to miR(Irr) (*P < 0.001 for all). Notably, the 
miR(5,B,7) cluster comprising all three VEGF-targeting miRNAs was 
able to downregulate the mVEGF reporter by 78 ± 2% (*P < 0.0001).
Subsequently, the miR(5,B,7) and the miR(Irr) clusters were 
inserted in the intron of pLV/CMV-intron-AsRED and pLV/
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VMD2-intron-AsRED constructs, generating the pLV/CMV-
miR(5,B,7)-AsRED, pLV/CMV-miR(Irr)-AsRED, pLV/VMD2-miR(5,B,7)-
AsRED, and pLV/VMD2-miR(Irr)-AsRED LV transfer plasmids. To test 
the efficacy of LV-delivered miRNAs, HEK-293 cells were trans-
duced with LV/CMV-miR(5,B,7)-AsRED or LV/CMV-miR(Irr)-AsRED, 
and melanoma cells were transduced with LV/VMD2-miR(5,B,7)-
AsRED or LV/VMD2-miR(Irr)-AsRED. Transduction efficiency was 
inspected by fluorescence microscopy and revealed strong AsRED 
expression in the vast majority of the cells as exemplified in Figure 
1d. Four days after transduction, cells were transfected with the 
psiCHECK-mVEGF reporter, and VEGF silencing was assessed by 
measuring RLuc/PLuc activity in cell extracts. Both promoters, 
CMV and VMD2, were able to significantly downregulate VEGF 
(38 ± 2% and 49 ± 5%, respectively) (Figure 3b).
Correct processing of all three miRNAs from the intron region was 
verified by northern blotting (Figure 3c). Total RNA was extracted 
from HEK-293 cells transfected with pcDNA3.1-based plasmids 
encoding the tricistronic miR(5,B,7), the irrelevant control miR(Irr), 
or clusters harboring only one of the anti-mVEGF miRNAs and 
two anti-HIV miRNAs (miR(5,S2,S3), miR(S1,B,S3), or miR(S1,S2,7)). 
Following polyacrylamide gel electrophoresis, mature miRNAs 
~21–23 nt long were visualized using miRNA-specific probes, des-
ignated probe 5, B and 7, respectively. Probe B gave rise to a much 
stronger signal compared to probe 5 and 7. The same hybridization 
Figure 1 Design and functionality of the multigenic LV vectors. (a) Schematics of the pLV/PE and multigenic LV expression cassettes. The LV transfer 
vector incorporates a promoter (CMV or the RPE-specific VMD2) that drives the expression of a single mRNA encoding both anti-mVEGF miRNAs 
(miR(5,B,7)) and a transgene (AsRED or PEDF). If indicated, the LV vectors also encode eGFP driven by the PGK promoter as a reporter gene (PE). 
Restriction sites used for cloning are shown. Arrows in a indicate PCR primer binding sites. (b) Assessment of splicing of pre-mRNA by PCR analysis. 
RNA was purified from HEK-293 cells transduced with LV-CMV-intron-AsRED-PE 48 hours after transduction. Products from cDNA synthesis with (+RT) 
and without (-RT) reverse transcriptase were used as template in a PCR. If the mRNA is spliced, the expected size of the PCR product is 791 bp. pLV-
CMV-intron-AsRED-PE plasmid DNA was used as unspliced control (UC) with a product size expected to be 1,270 bp and H2O as nontemplate control 
(NTC). (c) Functional titer determined by flow cytometry analysis of HEK-293 cells (mean ± SD). (d) Immunofluorescence analysis of eGFP and AsRED 
expression in three different cell lines (HEK-293, ARPE-19, and melanoma cells) 4 days after transduction with 100 ng p24 LV-VMD2-intron-AsRED-PE. 
Scale bar = 100 µm. ARPE-19, human retinal pigment epithelium cells; CMV, cytomegalovirus; cPPT, central polypurine tract; eGFP, enhanced green 
fluorescent protein; HEK-293, human embryonic kidney cells; LTR, long terminal repeat; LV, lentiviral; -PE, PGK-eGFP; PGK, phosphoglycerate kinase 1 
promoter; polyA, bovine growth hormone polyadenylation signal; ψ, packaging signal; RRE, Rev-responsive element; RT, reverse transcriptase; SA, splice 
acceptor; SD, splice donor; TU, transduction unit; U3 (SIN), Self-inactivating deletion in the U3 region; VMD2, vitelliform macular dystrophy 2 promoter; 
WPRE, woodchuck hepatitis virus posttranscriptional regulatory element.
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Figure 2 Histological analysis of LV transduction in the mouse retina 21 days after subretinal injection of 30 ng p24 LV/VMD2-miR(5,B,7)-AsRED-PE. (a) 
eGFP (green) and (b) AsRED (red) expression in the superior half of the retina, delineated by the large dotted square in c. (c) The sagittal section through 
the retina is assembled from several individual merged (eGFP and AsRED) illustrations of retinal transduction. The retina is stained with DAPI to show 
cell nuclei (blue). Expression of eGFP and AsRED reveal localization of LV/VMD2-miR(5,B,7)-AsRED-PE to the RPE cell layer primarily in close vicinity to 
the injection site located in the superior half of the retina. The areas delineated by the dotted squares are magnified in image a, b, d, and e. Section 
orientation is shown in the lower right corner. (d) Individual (eGFP and AsRED) and merged images revealing simultaneous expressing of eGFP and 
AsRED localized to the RPE cell layer, and (e) the inner and outer nuclear layers. The eGFP and AsRED signals are enhanced in e compared to d. Scale 
bars = 50 µm.
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conditions were applied for all three probes, and the obvious differ-
ence in processed miRNAs detected on the blot possibly reflected 
suboptimal hybridization conditions for probe 5 and 7, although 
ineffective processing of the miRNAs by the core machinery of the 
RNAi pathway could not be ruled out. Similar amounts of miRNA 
were processed from miR(5,S2,S3), miR(S1,B,S3), or miR(S1,S2,7) 
compared to miR(5,B,7) (Figure 3c), indicating that miRNA process-
ing was not affected by the sequence of adjacent miRNAs in the 
cluster.
Our studies of miRNA expression and processing indicate that 
miRNAs are processed correctly from the intron-based miRNA 
cluster and are capable of downregulating VEGF expression, when 
expressed from the versatile LV vector.
Inhibition of in vitro tube formation by anti-VEGF miRNAs
Following the demonstration of significant VEGF knockdown by 
miR(5,B,7) in HEK-293 cells, we next wanted to investigate the angio-
genic potential of LV-transduced human umbilical vein endothelial 
cells (HUVECs). The angiogenic potential of LV/CMV-miR(5,B,7)-
AsRED-transduced HUVECs was assessed by quantifying the sprout-
ing activity and capillary network complexity in the in vitro tube 
forming assay (Figure 4a). VEGF knockdown by the miR(5,B,7) clus-
ter resulted in significantly smaller cell covered areas, shorter tube 
length, and fewer branching points and loops after 4 hours than 
in untransduced and LV/CMV-miR(Irr)-AsRED-transduced HUVECs 
(Figure 4b). This indicates an overall reduced angiogenic potential 
due to overexpression of the anti-VEGF miRNAs in HUVECs trans-
duced with LV/CMV-miR(5,B,7)-AsRED. Furthermore, the data sug-
gest that miRNA expression easily can be indirectly assessed by 
the concomitant AsRED expression from our LV constructs, since 
significant inhibition of VEGF-mediated tube formation and red 
fluorescence was found in cells simultaneously (Figure 4a, lower 
panel).
Pigment epithelium-derived factor expression from the versatile LV 
vectors
The AsRED gene was replaced with the PEDF gene and expression 
of pigment epithelium-derived factor (PEDF) from the multigenic LV 
vectors was assessed by immunostaining (Figure 5a) and by west-
ern blotting (Figure 5b) of HUVECs transduced with LV/CMV-intron-
PEDF-PE. eGFP was broadly distributed in analyzed cells (Figure 5a, 
upper), whereas PEDF immunostaining indicated localization in the 
endoplasmic reticulum near the nucleus and in secretory vesicles trav-
elling towards the edge of the cell, as expected for a secretory protein 
(Figure 5a, lower). PEDF immunostaining of a negatively anti-PEDF 
stained HUVEC served as a negative control (upper left corner in pan-
els in Figure 5a). The lack of PEDF expression in this cell reflected that 
not all cells were transduced under the experimental conditions used.
PEDF expression from our LV construct was supported by western 
blotting revealing an immunoreactive band of ~50 kDa, represent-
ing PEDF protein, from both cell lysate and medium from HUVECs 
transduced with LV/CMV-intron-PEDF-PE. As expected, protein 
expression increased with increasing amounts of p24, although 
the amount of secreted protein seemed to reach a saturation point 
when HUVECs were transduced with more than 100 ng p24.
The functionality of PEDF was assessed by measuring the amount 
of thrombospondin-1 (TSP-1) mRNA, which is regulated by PEDF in 
HUVECs, and by investigating the angiogenic potential of LV/CMV-
intron-PEDF-PE-transduced HUVECs. As expected, the amount of 
PEDF mRNA increased in HUVECs, when cells were transduced with 
increasing amounts of p24 LV (Figure 5c, upper). TSP-1 mRNA lev-
els were found to be significantly increased in HUVECs transduced 
Figure 4 Inhibition of tube formation in LV/CMV-miR(5,B,7)-AsRED transduced HUVECs. 1 × 105 HUVECs were transduced with 100 ng p24 LVs 
corresponding to a MOI of 3. (a) Representative phase contrast and red fluorescence (AsRED) images of tube formation of untransduced HUVECs (upper 
panel) and LV/CMV-miR(Irr)-AsRED (mid panel) and LV/CMV-miR(5,B,7)-AsRED (lower panel) transduced HUVECs. Scale bar = 200 µm (b) Quantitative 
analysis of tube formation (mean ± SD). *Statistically significant.
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Figure 5 Expression of PEDF from the multigenic LV vectors in HUVECs. (a) Immunostaining of a HUVEC expressing PEDF after LV/CMV-intron-PEDF-PE 
transduction (100 ng p24 corresponding to a MOI of 3). Staining of the nucleus is shown in blue (DAPI), eGFP expression in green (upper), and anti-
PEDF in red (lower). In the upper left corner, a negative anti-PEDF-stained control cell is shown. Scale bar = 20 µm. (b) Western blot analysis of 15 µg 
total protein extract (upper) and 24 µl medium (lower) from HUVECs transduced with 20, 100, or 200 ng p24 of LV/CMV-intron-PEDF-PE, corresponding 
to MOIs of 0.6, 3, and 6, respectively. The negative control (LV) is HUVECs transduced with 100 ng p24 LV/CMV-intron-AsRED-PE, corresponding to a 
MOI of 3. The cell lysate and medium fractions were subjected to electrophoresis, blotting and immunostaining using a mouse anti-PEDF antibody. 
As a loading control for the cell lysate samples, a rabbit antibody against β-actin was used. The positions of PEDF and β-actin are indicated on the 
right. (c) RNA harvested from HUVECs transduced with 20, 100, or 200 ng p24 of LV/CMV-intron-PEDF-PE (corresponding to MOIs of 0.6, 3 and 6, 
respectively) or with 100 ng p24 LV/CMV-intron-AsRED-PE (corresponding to a MOI of 3) was subjected to quantitative RT-PCR using PEDF, TSP-1, 
and HPRT primers. The PEDF (upper) and TSP-1 (lower) mRNA concentrations in the LV/CMV-intron-PEDF-PE transduced HUVECs are normalized to 
the HPRT mRNA concentration and presented relative to LV/CMV-intron-AsRED-PE transduced HUVECs (mean ± SD). (d) The angiogenic potential of 
LV/CMV-intron-PEDF-PE transduced HUVECs was not found to be significantly reduced compared to LV/CMV-intron-AsRED-PE transduced HUVECs. 
Quantitative analysis of cell covered area, total tube length, total number of branching points and loops are shown (mean ± SD). The values for the LV/
CMV-intron-PEDF-PE transduced HUVECs were not significantly different from the other groups. *Statistically significant. HPRT, Hypoxanthine-guanine 
phosphoribosyl transferase; PEDF, pigment epithelium-derived factor; TSP-1, Thrombospondin-1.
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with 200 ng LV/CMV-intron-PEDF-PE 6 days after transduction com-
pared to control cells transduced with LV/CMV-intron-AsRED-PE 
(Figure 5c, lower). However, the angiogenic potential was not found 
to be significantly reduced in HUVECs transduced with 100 ng LV/
CMV-intron-PEDF-PE compared to HUVECs transduced with LV/
CMV-intron-AsRED-PE (Figure 5d). This finding suggested that the 
amount of PEDF expressed from the transduced cells was not high 
enough to have an effect on tube formation in this assay set-up.
These results demonstrate efficient expression and functionality 
of PEDF from the multigenic LV vectors and, moreover, regulation of 
the amount of expressed PEDF by adjusting the levels of p24.
To verify parallel expression of miRNAs and PEDF codelivered by 
the multigenic LV particle, HEK-293 cells were transduced with LV/
CMV-miR(5,B,7)-PEDF-PE or LV/CMV-miR(Irr)-PEDF-PE. The trans-
duction efficiency was inspected by fluorescence microscopy and 
revealed, as expected, strong AsRED expression in the majority of the 
cells (data not shown). Four days after transduction, cells were divided 
in two groups. Cells from one group was immediately fixated and the 
PEDF expression was analyzed by means of immunostaining. In the 
other group, the cells were transfected with the psiCHECK-mVEGF 
reporter, and VEGF silencing was assessed by measuring RLuc/PLuc 
activity in cell extracts. As shown in Figure 6, transduction with LV/
CMV-miR(5,B,7)-PEDF-PE vector resulted in robust miRNA-directed 
downregulation of VEGF expression and, in parallel, overexpression of 
PEDF. The LV/CMV-miR(5,B,7)-PEDF-PE vector was able to downregu-
late the mVEGF reporter by ~40% compared to the LV/CMV-intron-
PEDF-PE vector (*P < 0.0035) (Figure 6a). This is almost identical to the 
data obtained by using the LV/CMV-miR(5,B,7)-AsRED, supporting the 
notion that insertion of PEDF instead of AsRED does not change the 
titer (see Figure 3b). As shown in Figure 6b, immunostaining analysis 
of cells transduced with LV/CMV-miR(5,B,7)-PEDF-PE revealed expres-
sion of PEDF protein with an apparent localization in the endoplasmic 
reticulum near the nucleus as well as in secretory vesicles, which is 
similar to the staining pattern observed in transduced HUVECs (see 
Figure 5a). In summary, the multigenic lentiviral vectors demonstrate 
robust miRNA-directed downregulation of VEGF expression, lead-
ing to reduced angiogenesis, and parallel impairment of angiogenic 
pathways by codelivering PEDF.
DISCUSSION
Our results show functionality and efficacy of complex LV vectors 
with potential applicability in the development of an alternative 
combinational treatment for retinal neovascular diseases. This is 
supported by our results showing (i) lentiviral titers sufficient for in 
vivo applications of complex constructs despite multiple gene cas-
settes and volume limitations, as demonstrated by eGFP and AsRED 
coexpression in mouse retina following subretinal delivery, (ii) sig-
nificant downregulation of VEGF expression as well as inhibition of 
VEGF-mediated tube formation in vitro by LV-mediated expression 
of multiple anti-VEGF miRNAs, (iii) coexpression of multiple miRNAs 
with therapeutic proteins, such as the multifunctional protein PEDF 
from the multigenic vector, and (iv) targeted transcription of a sin-
gle mRNA, encoding miRNAs and protein from the LV construct, in 
retinal target cells such as the RPE cells by incorporation of a tissue-
specific promoter.
Current treatment options for patients suffering from exudative 
AMD, including anti-VEGF and photodynamic therapy, all have in 
common that repeated treatments are necessary; for some of the 
treatments, monthly therapy is required. Patients as well as the 
health care system are struggling with the burden that comes with 
the need of monthly care involving an invasive therapy that for 
most patients will require a lifetime of treatment. Additionally, some 
patients do not benefit from established treatments. Fortunately, 
several new therapies are appearing, some of which have the poten-
tial to once more, noticeably change the treatment modality for 
AMD patients. These modalities revolve around gene therapy, with 
proof of concept for ocular gene therapy established with treatment 
of Leber congenital amaurosis.16–18 At present, several gene therapy-
based treatments are being evaluated in clinical trials. Most of them 
include expression of an antiangiogenic protein from viral vectors: 
PEDF from adenovirus,19 soluble VEGF receptors (sFlt-1 (ref. 20) or 
sFLT01 (ref. 21)) from AAV or Endostatin and Angiostatin from an LV 
vector.22 A few have involved delivery of synthetic siRNAs, but two 
out of three unfortunately failed to meet the efficacy requirements.
In this study, we have designed and evaluated multigenic LV vec-
tors with combined expression of multiple anti-VEGF miRNAs and 
proteins. With the miRNA-based delivery approach, it is possible to 
simultaneously target (i) multiple regions in a single mRNA or (ii) 
several different genes, thereby providing a broader applicability 
allowing fine-tuned expression and enhanced cellular processing. 
This approach has been applied for knocking down three differ-
ent genes from a single lentiviral vector.23 In addition, we have in 
a previous study shown effectfull miRNA-mediated knockdown 
of VEGF from a single AAV vector expressing three different anti-
VEGF siRNAs.12 We believe LV-delivered anti-VEGF miRNAs have 
Figure 6 Simultaneous expression of miRNAs and PEDF from the 
multigenic LV/CMV-miR(5,B,7)-PEDF-PE vectors in HEK-293 cells. Crude 
LV/CMV-miR(5,B,7)-PEDF-PE or LV/CMV-intron-PEDF-PE was added to 
1 × 106 HEK-293 cells corresponding to a MOI of ~2.5. (a) miRNA-mediated 
RLuc-VEGF knockdown 6 days after transduction in LV/CMV-miR(5,B,7)-
PEDF-PE, or LV/CMV-intron-PEDF-PE treated HEK-293 cells demonstrated 
by using the dual luciferase assay. Nontransduced (naïve) HEK-293 cells 
were used as negative control. Expression of Renilla luciferase activity 
(RLuc) was normalized to the expression of the internal P. photinus 
luciferase (PLuc) as a transfection control and values are presented 
relative to levels in cells transduced with LV/CMV-intron-PEDF-PE (mean 
± SD). *Statistically significant. (b) Immunostaining of HEK-293 cells 
expressing PEDF after LV/CMV-miR(5,B,7)-PEDF-PE transduction. Staining 
of the nucleus is shown in blue (DAPI), eGFP expression in green (upper), 
and anti-PEDF in red (lower). Scale bar = 10 µm. PLuc, Firefly luciferase; 
RLuc, Renilla luciferase.
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significant advantage over synthetic siRNAs in that they are con-
tinuously expressed endogenously in target cells following a 
single injection. Additionally, utilization of miRNA-based delivery 
 strategies  overcomes the obstacles encountered with siRNA-based 
 treatments, such as sequence- and target-independent toll-like 
receptor 3 mediated suppression of angiogenesis,9 and are less 
prone to interfere with the endogenous miRNA processing com-
pared to shRNA delivered with strong polymerase III promoters, 
thus exhibiting an improved safety profile.24–26 Even though inser-
tion of a second expression cassette (CMV-intron) resulted in 12-fold 
reduction in the titer, which is similar to previous findings,27 the bidi-
rectional vectors demonstrated robust miRNA-directed downregu-
lation of VEGF expression and parallel overexpression of PEDF.
After investigating the basic functionality of the multigenic LV 
vectors, we wanted to ensure that we could obtain titers sufficient 
for in vivo applications. For in vivo studies, we included an RPE-
specific promoter (VMD2) to limit transgene expression to RPE cells, 
the cells responsible for overexpression of VEGF in AMD patients.28 
The transduction profile and efficiency of an LV vector incorporat-
ing the VMD2 promoter were evaluated in mice following subretinal 
delivery, and reporter gene expression demonstrated efficient gene 
transfer limited to RPE cells, as shown previously by other groups.29,30
When we combined two or three anti-VEGF miRNAs in the same 
cluster, we observed in this study an improved VEGF silencing 
effect compared to our previous studies.12 We found that substi-
tution of the miRNA in the second position significantly improved 
the anti-VEGF effect of the miRNA clusters compared to our previ-
ous results,12 where we obtained a reduced VEGF silencing effect 
when miR(9) or miR(10) was incorporated in mono- or bicistronic 
constructs. These results indicate that the poor functionality can be 
rescued by proper design of the miRNA. However, the total VEGF 
silencing found in this study (78 ± 2% in HEK-293) was comparable 
to our previous study (75 ± 1% in ARPE-19).12
LV-mediated delivery of anti-VEGF miRNAs was able to signifi-
cantly downregulate VEGF in HEK-293 (38 ± 2%) and melanoma 
cells (49 ± 5%). The difference in VEGF knockdown efficacy of the 
miR(5,B,7) in the cotransfected cells compared to the LV-transduced 
cells, is believed to be due to the different amount of psiCHECK vec-
tors used as well as a difference in the ratio of miRNA to VEGF reporter 
expression cassettes in the cells. The latter is due not only to dif-
ferences in study design, but also in cellular uptake of LV-delivered 
transduction and plasmid-based transfection mechanisms.31
We have demonstrated that anti-VEGF miRNAs can inhibit tube 
formation in vitro. HUVECs transduced with the LV/CMV-miR(5,B,7)-
AsRED construct also exhibited red fluorescence, indicating func-
tional expression of both miR(5,B,7) and AsRED in the HUVECs. 
Incorporation of reporter genes such as AsRED or eGFP allows 
easy visualization of transgene expression in vitro as well as in vivo. 
Furthermore, miRNA expressing cells can be easily traced by the 
concomitant AsRED expression.
AsRED was exchanged with PEDF, and expression was confirmed 
by immunostaining and western blot. Functional expression was 
verified by qPCR, demonstrating increased amounts of TSP-1 
mRNA, an endogenous angiogenic inhibitor that inhibits prolifera-
tion of endothelial cells, in HUVECs transduced with 200 ng p24 
of LV/CMV-intron-PEDF-PE, which is in accordance with previous 
findings.32 We could not demonstrate an antiangiogenic effect 
in the tube forming assay. Others have been able to show inhibi-
tion of VEGF-mediated angiogenesis in the tube forming assay,33,34 
and shown that addition of recombinant PEDF can inhibit tube 
formation in this assay.35 We believe that our finding can be due 
to sub-optimal assay conditions including insufficient amounts 
of PEDF. In this assay, HUVECs were transduced with 100 ng of 
p24, which is likely to be insufficient for PEDF to have an effect. A 
delayed effect of secreted PEDF from the transduced HUVECs was 
precluded by inspection after 24 hours also and by utilization of 
conditioned medium (data not shown).
Based on our data, a combination therapy of LV-delivered antian-
giogenic miRNAs and protein for treatment of intraocular neovascu-
lar diseases may be proposed. Efficient coexpression of miRNAs and 
two proteins from a single viral vector may minimize the viral load 
necessary to obtain a therapeutic effect and thereby reduce the risk 
of insertional mutagenesis as well as the immune response against 
viral proteins. Furthermore, the subretinal delivery strategy has vol-
ume limitations underscoring the applicability of efficient, multi-
genic viral vectors for retinal gene transfer. For immunotherapy for 
cancer patients, Okamoto et al. have developed murine leukemia 
virus-based vectors encoding siRNAs to knockdown endogenous 
T-cell receptor (TCR) genes and a therapeutic siRNA-resistant tumor 
antigen-specific TCR simultaneously.36 The LV vectors were chosen 
in the present study due to their ability to transduce nondividing 
cells and in contrast to the AAV vectors, they have a large packaging 
capacity, required for packing of the multigenic and PE expression 
cassettes. Presently there is a rapidly growing interest in the LV vec-
tors for ocular gene therapy, and three LV-based clinical trials are 
currently open (clinicaltrials.gov). Concerns regarding insertional 
mutagenesis can be further reduced by utilizing integrase-defec-
tive LV vectors.37
In conclusion, our results show expression of therapeutic anti-
VEGF-miRNAs and PEDF from a single cassette and efficient gene 
transfer to mouse retinal cells when delivered by the versatile LV 
vector, demonstrating the potential applicability of multigenic LV 
vectors in ocular anti-VEGF gene therapy, including combination 
therapy for treatment of exudative AMD.
MATeRIAlS AND MeTHODS
Cell culture, transfection, and transduction
Five different cell lines were used in this study. A human adult retinal pig-
ment epithelial cell line (ARPE-19; catalog number CRL-2302; American Type 
Culture Collection, Boras, Sweden) was maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM)/F12 Nutrient Mixture;1:1 (Gibco, Invitrogen, 
Taastrup, Denmark) with 10% fetal calf serum (Sigma-Aldrich, Broendby, 
Denmark), 0.06 mg/ml penicillin (FarmaPlus, Oslo, Norway), 0.1 mg/ml 
streptomycin and 0.29 mg/ml glutamine (both Sigma-Aldrich). HEK-293 
cells (catalog number CRL-1573; American Type Culture Collection), HEK-
293T cells,38 and melanoma cells13 were maintained in DMEM (Gibco; 
Invitrogen) containing 0.29 mg/ml glutamine (Sigma-Aldrich), 0.06 mg/ml 
penicillin (Farma-Plus) and 0.1 mg/ml streptomycin (Sigma-Aldrich) and 
supplemented with 10% fetal calf serum (Sigma-Aldrich). Human umbili-
cal vein endothelial cells (HUVECs; catalog number CC-2517, Lonza, Basel, 
Switzerland) were maintained in endothelial cell growth medium 2 (EGM2) 
(BioNordika, Herlev, Denmark) supplemented with 0.06 mg/ml penicillin 
(Farma-Plus) and 0.1 mg/ml streptomycin (Sigma-Aldrich) and for the tube 
forming assay, endothelial cell growth medium (EGM) (BioNordika) supple-
mented with 0.06 mg/ml penicillin (Farma-Plus) and 0.1 mg/ml streptomycin 
(Sigma-Aldrich) was used.
Cells were cultivated in tissue culture flasks or plates (TPP Techno 
Plastic Products AG, Trasadingen, Switzerland) at 37 °C with 5% (v/v) CO2 
as described previously.39 All transfection experiments were carried out in 
triplicates or five copies at 25% confluency using X-tremeGENE 9 (Roche 
Applied Science, Hvidovre, Denmark) for transfection of HEK-293 cells (ratio 
DNA:transfection reagent 1:4) and JetPrime transfection reagent for trans-
fection of melanoma cells (ratio DNA:transfection reagent 1:2).
Before transduction of HEK293, ARPE-19, and HUVECs the culture 
medium was removed and replaced with fresh culture medium containing 
8 µg/ml polybrene (Sigma-Aldrich). For transduction of melanoma cells, no 
polybrene was used.
9Antiangiogenic activity of multifunction LV vectors
AL Askou et al.
Molecular Therapy — Methods & Clinical Development (2015) 14064© 2015 The American Society of Gene & Cell Therapy
Vector construction
The design of the miRNAs has been described in our previous study.12 In this 
study, we modified miR(5) and miR(7)12 to target murine VEGF164, and miR(B) 
was adapted from a previous study4 and modified to target murine VEGF164. 
miR(5), miR(B), and miR(7) were designed to perfectly match the mouse 
ortholog. The different miRNAs directed against mVEGF were inserted in the 
optimized miR-106b cluster driven by the cytomegalovirus (CMV) promoter 
(pCDNA3.1-based plasmid, designated pCM in this study)15 by independent 
replacement of each of the three anti-HIV miRNAs. Inserts were generated 
by PCR extension of partially annealed overlapping ~60-nucleotide oli-
gonucleotides (Eurofins MWG Operon, Ebersberg, Germany), followed by 
digestion with the appropriate restriction enzymes. Thus, in total, seven dif-
ferent clusters comprised of heterologous hairpin entities were generated 
by permutational insertions into the S1, S2, and S3 positions as XhoI/HindIII, 
EcoRI/BamHI or XbaI/SacII fragments, respectively. The resulting plasmids 
were named pmiR(x,y,z) (x,y,z being the order of the different anti-VEGF 
miRNAs). The anti-HIV miR-S1,S2,S3 cluster was used as an irrelevant control 
(referred to as miR(Irr)).
The multigenic LV vectors were generated by replacing the EF1α pro-
moter in pLV/EF1α-intron-PE (PE denotes the PGK-eGFP expression cas-
sette) with the CMV or the VMD2 promoter (L. Aagaard, unpublished). The 
CMV promoter was amplified from the pCM plasmid by PCR using Herculase 
II fusion DNA polymerase (Agilent Technologies, AH Diagnostics, Aarhus, 
Denmark) and CMV specific-primers harboring MluI and SalI restriction 
enzyme recognition sequences followed by digestion with MluI and SalI. 
Following MluI and SalI double digestion, the CMV sequence was inserted 
in the linearized pLV/EF1α-intron-PE plasmid replacing EF1α. The resulting 
vector was named pLV/CMV-intron-PE. The VMD2 promoter sequence was 
obtained from a previous study.29 The −585 to +38 bp sequence upstream 
of human VMD2 gene was synthesized by GenScript (Piscataway, NJ) flanked 
by MluI and SalI restriction sites. Following MluI and SalI double digestion, 
the VMD2 sequence was inserted in the linearized pLV/EF1α-intron-PE plas-
mid replacing EF1α. The resulting vector was named pLV/VMD2-intron-PE. 
The bovine growth hormone polyA site is utilized as termination sequence 
in the CMV/VMD2 expression cassette, whereas expression from the PE cas-
sette is terminated by the viral 3′LTR.
The constructs without the PE expression cassette are generated by 
removing PE by MluI and XhoI double digest followed by T4 DNA polymerase 
(New England Biolabs, Ipswich, MA) reaction to generate blunt ends and 
subsequently, the plasmid was religated.
AsRED was amplified from the pAAV2-siRNA vector (catalog number 
0914; Applied Viromics, Fremont, CA) by PCR using Herculase II fusion DNA 
polymerase (Agilent Technologies) and AsRED specific-primers harboring 
the XmaI restriction enzyme recognition sequence. Following XmaI diges-
tion, the AsRED sequence was inserted in the linearized pLV/CMV-intron-PE 
or pLV/VMD2-intron-PE plasmid. The resulting vectors were named pLV/
CMV-intron-AsRED-PE and pLV/VMD2-intron-AsRED-PE, respectively.
PEDF was acquired from Source BioScience (Cambridge, UK) as an Image 
cDNA clone (IMAGE ID 235156). PEDF was amplified from the vector har-
boring the Image Clone by PCR using Herculase II fusion DNA polymerase 
(Agilent Technologies) and PEDF specific-primers harboring the XmaI restric-
tion enzyme recognition sequence. Following XmaI digestion, the PEDF 
sequence was inserted in the linearized pLV/CMV-intron-PE or pLV/CMV-
intron plasmids. The resulting vectors were named pLV/CMV-intron-PEDF-PE 
and pLV/CMV-intron-PEDF, respectively.
The anti-VEGF miRNA miR(5,B,7) and irrelevant miR(Irr) clusters were 
amplified from the pCM/miR(5,B,7) and pCM/miR(Irr), respectively, by PCR 
using OneTaq DNA polymerase (New England Biolabs, Ipswich, MA) and prim-
ers harboring the BsiWI and NsiI restriction enzyme recognition sequences. 
Following BsiWI and NsiI double digestion, the miR(Irr) or miR(5,B,7) cluster 
sequences were inserted in the linearized pLV/CMV-intron-AsRED, pLV/CMV-
intron-AsRED-PE, pLV/CMV-intron-PEDF-PE, pLV/VMD2-intron-AsRED, and 
pLV/VMD2-intron-AsRED-PE plasmids. The resulting vectors were named 
pLV/CMV-miR(Irr)-AsRED, pLV/CMV-miR(5,B,7)-AsRED, pLV/CMV-miR(5,B,7)-
AsRED-PE, pLV/CMV-miR(5,B,7)-PEDF-PE, pLV/VMD2-miR(Irr)-AsRED, pLV/
VMD2-miR(5,B,7)-AsRED, and pLV/VMD2-miR(5,B,7)-AsRED-PE, respectively.
For generation of a dual luciferase reporter construct to serve as a plat-
form for testing the anti-VEGF miRNA clusters, the psiCHECK-mVEGF plas-
mid was produced. Changes in expression of the Renilla luciferase reporter 
gene fused to the mVEGF gene were used as an indicator of the efficacy of 
the anti-VEGF miRNAs. The mVEGF164 cDNA sequence (GenBank accession 
number BC061468.1) was synthesized by GenScript flanked by NotI and XhoI 
restriction sites and cloned into unique NotI and XhoI sites in the 3′-UTR of 
the Renilla luciferase gene of the psiCHECK-2 Vector (Promega, Stockholm, 
Sweden).
Plasmid DNA was purified using Plasmid Plus kits (Qiagen Nordic, 
Copenhagen, Denmark). All constructs were verified by restriction analysis 
and sequencing. Primer sequences are available upon request.
LV production, purification, and titer assessment
For cell studies, crude LV preparations (preps) were made and for subretinal 
injections, the LV preps were concentrated by ultracentrifugation. On day 
1.1 × 107 (or 4 × 106) HEK-293T cells were seeded in a p15 (or a p10) dish. On 
day 2, cells were transfected with calcium phosphate precipitates. Each of 
the p15 dishes were transfected with 9.1 µg pMD.2G, 7.3 µg pRSV-Rev, 31.5 
µg pMDLg/pRRE, and 31.5 µg pLV. The p10 dishes were transfected with 3.75 
µg pMD.2G, 3 µg pRSV-Rev, 13 µg pMDLg/pRRE, and 13 µg pLV The medium 
was replaced on day 3. On day 4, viral supernatants were harvested, and 
passed through a 0.45 µm filter (Millipore A/S, Hellerup, Denmark). LV par-
ticles produced for subretinal injections were further purified and concen-
trated by ultracentrifugation through a sucrose cushion at 25,000 rpm for 2 
hours in a SW28 rotor (Beckman Coulter, Fullerton, CA). Pellets were resus-
pended in phosphate-buffered saline (PBS) and stored at −80 °C.
Concentrations of HIV-1 p24 were measured by enzyme-linked immuno-
sorbent assay (ZeptoMetrix, Buffalo, NY) according to the manufacturer’s 
protocol. Number of transducing units per ml (TU/ml) was determined by 
flow cytometry. On day 1, 105 HEK-293 cells were seeded in six-well plates. 
On day 2, cells were transduced with crude virus with dilutions of 0.5, 10–1, 
and 10–2. On day 3, the medium containing virus was removed and replaced 
with 2 ml of fresh culture medium. On day 7, the cells were collected and 
washed in PBS before fixation in neutral buffered formalin (NBF). Flow 
analysis was performed to record the percentage of cells that were GFP and 
AsRED double positive compared to the negative control cells. For cells only 
expressing AsRED or GFP, the percentage of AsRED positive or GFP positive 
cells were used, respectively. Data were collected on a 4-laser LSRFortessa 
(BD Biosciences, San Jose, CA) and analyzed with FlowJo (Tree Star, Ashland, 
OR). A well that had between 1 and 20% of cells expressing GFP and/or 
AsRED was used to determine lentiviral titer by the formula: TU/ml = ((F × 
Cn)/V) × DF, where F is the frequency of GFP and/or AsRED-positive cells 
determined by flow cytometry; Cn is the total number of target cells infected; 
V is the volume of the transducing inoculum in ml and DF is the virus dilu-
tion factor. For each individual experiment, the estimated virus dose per cell 
(MOI) was based on the correlation that 1 pg HIV-1 p24 unit corresponds to 3 
TU as determined in HEK293 cells transduced with LV/CMV-intron-AsRED-PE.
Dual-luciferase assay
A dual luciferase reporter construct, psiCHECK-mVEGF, was generated 
as described previously11 to serve as a platform for testing the efficacy of 
the anti-VEGF miRNAs. To test the efficacy of the seven different anti-VEGF 
miRNA clusters, 2 × 104 HEK-293 cells were seeded in 24-well plates. The fol-
lowing day, cells were transfected with 40 ng psiCHECK-mVEGF plasmid and 
360 ng of the indicated plasmid harboring one of the seven different miRNA 
clusters per well (triplicates). Forty-eight hours after transfection, cells were 
lysed and luciferase levels analyzed using the Dual-Luciferase Reporter Assay 
System (Promega). To test the efficacy of miRNA clusters delivered by LV par-
ticles, 2 × 105 HEK-293 and melanoma cells in six-well plates were transduced 
with 100 ng p24 LV/CMV-miR(5,B,7)-AsRED, LV/CMV-miR(Irr)-AsRED, LV/CMV-
miR(5,B,7)-PEDF-PE, LV/CMV-intron-PEDF-PE or LV/VMD2-miR(5,B,7)-AsRED 
and LV/VMD2-miR(Irr)-AsRED particles, respectively. Four days after trans-
duction, 3 × 103 LV transduced HEK-293 or melanoma cells were seeded in 
96-well plates (n = 5). The following day, cells were transfected with 48 or 
96 ng psiCHECK-mVEGF plasmid and 48 hours after transfection, cells were 
lysed and luciferase levels analyzed using the Dual-Glo Luciferase Assay 
System (Promega). Changes in the expression of Renilla luciferase (Rluc) 
were normalized to Photinus pyralis luciferase (PLuc) and presented relative 
to levels in cells transduced with miR(Irr).
RNA isolation, cDNA synthesis, and PCR analysis
RNA was extracted from LV/CMV-intron-AsRED-PE transduced HEK-293 
cells 48 hours after transduction using RNeasy Mini Kit and DNase treat-
ment according to the manufacturer’s instructions (Qiagen Nordic). cDNA 
was generated by reverse transcription of 0.5 µg RNA using oligo (dT), ran-
dom hexamer primers, and iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). A standard PCR amplification was performed using ~10 ng 
cDNA or plasmid DNA as template and primers annealing in the 5′ exon 
sequence and the AsRED sequence amplifying a large 1,270 bp frag-
ment if no splicing occurs, and a small 791 bp fragment if splicing occurs. 
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The resulting PCR fragments were subjected to agarose gel electrophoresis. 
All primer sequences and PCR conditions are available upon request. RT-PCR 
was performed as previously described.11
miRNA purification and northern blot analysis
HEK-293 cells were transfected in culture flasks (surface area 75 cm2) at 
25% confluency using X-tremeGENE 9 (Roche Applied Science). Total RNA 
was isolated 48 hours after transfection using the mirVana miRNA Isolation 
Kit (Ambion, Austin, TX). For detection of miRNA expression, 20 µg of total 
RNA was electrophoresed in 10% denaturing polyacrylamide gel elec-
trophoresis (Criterion Precast gel 10% TBE-urea (BioRad, Copenhagen, 
Denmark)) in 1x TBE buffer for 30 minutes at 200 V together with a RNA 
size marker (decade marker RNA; Ambion). The RNA was transferred to a 
positively charged nitrocellulose membrane, Amersham Hybond-N (GE 
Healthcare, Little Chalfont, UK) by electroblotting (Trans-blot SD semi-dry 
transfer cell; BioRad). Ultraviolet-fixed membranes were hybridized over-
night in PerfectHyb solution (Sigma-Aldrich, St Louis, MA) at 42 °C with 
purified 5′ 32P-labeled oligos complementary to the predicted mature 
miRNA strand. The oligo probes (10 pmol) were end-labeled with PNK (10 
units; NEB) and γ32P-ATP (10 µCi) in 10 µl reactions for 1 hour, and puri-
fied with G-25 Sephadex spin-columns (GE Healthcare). Hybridized mem-
branes were washed twice with 6 × SSC/0.2% SDS, and then twice with 2 
× SSC/0.1% SDS, before exposure to film (CL-XPosureTM Film, Rockford, 
IL). Probe 5: 5′-GGATGTCTACCAGCGAAGCTA-3, probe B: 5′-AAACCTCAC-
CAAAGCCAGCAC, probe 7: AGACAGAACAAAGCCAGAAAA, U6 small nuclear 
RNA(snRNA)-specific probe: 5′-TATGGAACGCTTCTCGAATT-3.
Western blot analysis
HUVECs were transduced in six-well plate at 25% confluency with 20, 100, or 
200 ng p24 LV/CMV-intron-PEDF-PE or 100 ng p24 LV/CMV-intron-AsRED-PE 
as negative control, and subsequently subcultured in T25 flasks. Harvest, 
lysis and western blotting were performed as described previously.40 In 
short, cells were lysed 5 days after transduction in 100 µl of lysis buffer. 15 µg 
of total protein or 24 µl medium were electrophoresed on a 12% polyacryl-
amide gel (Mini-PROTEAN TGX gels; BioRad) together with the Precision Plus 
Protein Standard marker (BioRad). Following transfer to a Trans-Blot Turbo 
PVDF Membrane (Bio-Rad Laboratories), PEDF was detected using mono-
clonal mouse antipigment epithelium-derived factor antibody (MAB1059; 
Millipore). As a loading control, rabbit polyclonal antibody against β-actin 
(Abcam 8227–50; Abcam, Cambridge, MA) was used. Detection was per-
formed using secondary horseradish peroxidase-conjugated polyclonal 
goat antimouse and polyclonal goat antirabbit antibodies, respectively 
(numbers P0447 and P0448; Dako, Glostrup, Denmark). Bound antibodies 
were visualized with SuperSignal West Dura Extended Duration Substrate 
(Thermo Scientific, Waltham, MA) on an ImageQuant LAS4000 digital imag-
ing system (GE Healthcare, Cleveland, OH).
Immunostaining
HUVECs were transduced in six-well plates at 25% confluency with 100 ng 
p24 LV/CMV-intron-PEDF-PE or LV/CMV-intron-AsRED-PE and subsequently 
subcultured in slide flasks. Approximately 1 × 106 HEK-293 cells were trans-
duced in p10 dishes with 5 ml LV/CMV-miR(5,B,7)-PEDF-PE. Five days after 
transduction, the cells were fixed in 4% paraformaldehyde (Hounisen, 
Risskov, Denmark) and stained with mouse monoclonal PEDF antibody 
(Millipore MAB1059) as described previously.39 Detection was performed 
using secondary Alexa Flour 568 goat antimouse antibody (catalog number 
A11004; Invitrogen). Nuclei were stained with 4′,6-diamidino-2-phenylin-
dole (Sigma-Aldrich). Cells were visualized using a confocal laser scanning 
microscope (LSM 710, Zeiss, Jena, Germany).
Tube forming assay
Day 1, 1 × 105 HUVECs were seeded in six-well plates and transduced with 
100 ng p24 LV/CMV-miR(Irr)-AsRED or LV/CMV-miR(5,B,7)-AsRED the following 
day. Day 5, the cells were subcultured in T25 flask. Day 7, the culture medium 
was changed from EGM-2 to EGM (without VEGF). Day 8, 1 × 104 cells were 
seeded onto 10 µl BD matrigel (Basement Membrane Matrix, Growth Factor 
Reduced) (BD Biosciences) in a 15-well µ-Slide Angiogenesis ibiTreat (Ibidi 
GmbH, Planegg/Martinsried, Germany) in EGM medium. After 4 hours, tube 
formation was inspected by fluorescence microscopy (Leica DM IRBE) and 
images captured with a Leica DFC 320 camera. One photo was taken in the 
center of the well. Cell covered area, tube length, total number of branching 
points and loops was quantified with WimTube image analysis (Ibidi).
In the tube forming assay performed with LV/CMV-intron-AsRED-PE and 
LV/CMV-intron-PEDF-PE transduced HUVECS, cells were seeded in the con-
ditioned EGM medium that was removed from the cells before harvest on 
day 8.
Animals
For the ocular injections, C57BL/6J mice were purchased from Charles 
River (Arbesle, France) and maintained under a 12:12 hours light/dark 
cycle. The animals were handled in accordance with the statement of the 
“Animals in Research Committee” of the Association for Research in Vision 
and Ophthalmology, and protocols were approved by the local Swiss insti-
tutional committee, the “Service de la consommation et des affaires vétéri-
naires du canton de Vaud” (authorization VD#1367.3).
Subretinal LV injections
Subretinal injections were performed as described previously.11 The final 
dose of LV/VMD2-miR(5,B,7)-AsRED-PE (two mice, bilateral injections) was 
30 ng p24 per eye in a total volume of 2 µl.
Cryosectioning and histological analysis
Twenty-one days after the subretinal injection, eyes were enucleated, fixed, 
and cut as previously described.
For histological analysis, the 7-µm sections were thawed and rehydrated 
with PBS + 1% TritonX-100. Nuclei were stained with 4′,6-diamidino-2-phe-
nylindole (Sigma-Aldrich) and after washing with PBS, the sections were 
mounted in Mowiol (Sigma-Aldrich). Sections were analyzed for eGFP 
and AsRED expression by fluorescence microscopy (Leitz DM RB; Leica 
Microsystems GmbH, Wetzlar, Germany) and images captured with a Leica 
DFC 360 FX camera and associated software (Leica Application Suite, ver-
sion 3).
Statistical analysis
Data are presented as the mean ± SD. Statistical differences between two 
groups were evaluated using Student’s t-test and statistical differences 
between more than two groups were evaluated by linear regression analy-
sis. P < 0.05 was considered statistically significant.
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